A kind of tripterygium wilfordii extract and its preparation method and application
Through the treatment of ethyl acetate extract and purification of polyamide column chromatography, the toxic side effects and poor solubility of tripod vine extract were solved, and the low-toxic and efficient tripod vine extract was achieved, which significantly improved the rheumatoid arthritis. Treatment effect.
Patent Information
- Application Number
- CN202311584171.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-11-25
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2043-11-25
AI Technical Summary
The existing Triplet Vine extract has toxic side effects, narrow treatment window, poor solubility and low bioavailability in the treatment of autoimmune diseases such as rheumatoid arthritis, which limits its clinical application.
The ethyl acetate extract was concentrated and redissolved under reduced pressure, combined with chemical method, enzymatic method or bionic method, and purified by polyamide column chromatography to adjust the pH to below 3.5 to obtain a low-toxic Tribute Vine extract.
It significantly improves the efficacy of Triton Vine extract and reduces toxicity. The effect of treating rheumatoid arthritis is better than that of existing Triton Vine preparations and has no obvious toxicity.
Smart Images

Figure CN117338831B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of medicine, and in particular relates to a low-toxic tripterygium wilfordii extract and a preparation method and application thereof. Background Art
[0002] Rheumatoid arthritis is a systemic autoimmune disease that mainly manifests as bone and cartilage damage and involves multiple genes, multiple factors, and complexity. Severe cases can lead to disability. Compared with the huge market potential of immunosuppressants, the selection of small molecule chemical drugs for rheumatoid arthritis has obvious limitations. Among the new drugs approved by the FDA in recent years, small molecule drugs still occupy an absolute advantage, but with the limited discovery of molecular types and molecular skeleton structure diversity, the number of new molecular entities and small molecule innovative drugs has decreased year by year. Natural products and their metabolites have a diversity of molecular structures, and after natural selection and evolution, their structural diversity has a natural advantage in their use in disease prevention and treatment, and has always been an important source of new drug research and development of small molecule chemical drugs.
[0003] The genus Tripterygium mainly includes three species: Tripterygium wilfordii Hook.f., Tripterygium regelii Sprague et Takeda, and Tripterygium hypoglaucum (Levl.) Hutch. The history of its use in autoimmune diseases can be traced back thousands of years. Tripterygium wilfordii tastes pungent, bitter, cold, and toxic. Its definite anti-inflammatory and immunosuppressive pharmacological activities are widely used in the treatment of autoimmune diseases such as rheumatoid arthritis. Currently, there are 42 Chinese medicine preparations on the market, which are widely used clinically. The chemical components of Tripterygium wilfordii plants mainly include sesquiterpenoid alkaloids, diterpenoids, and triterpenoids. Among them, the total alkaloid content of Tripterygium wilfordii is about 0.07-0.29%, which plays an important role in immunosuppression. The structure of tripterygium wilfordii sesquiterpenoid alkaloids is a dihydrofuran sesquiterpenoid, and the reported structures mainly include wilfordate / evoninate, hydroxy-wilfordate / evoninate and iso-wilfordate / evoninate. Tripterygium wilfordii sesquiterpenoid alkaloids are a class of sesquiterpenoid compounds with a high oxygen content. The structure is characterized by a special macrocyclic dilactone skeleton structure. It is a lactone composed of two parts: 2-(carboxyalkyl)nicotinic acid and polyoxygenated dihydro-beita-agarofuran sesquiterpenoid. The hydroxyl groups of the sesquiterpene part are usually esterified by various organic acids, including acetic acid, benzoic acid, furanic acid, nicotinic acid and fatty acids, to form different types of alkaloids; the 2-(carboxyalkyl) nicotinic acid part is mainly derived from acetylic acid, vitamin acid, hydroxyvitamin acid or their homologues. At the same time, the difference in the 2-(carboxyalkyl) nicotinic acid part is the core of the differences in the macrocyclic dilactone skeleton structure, and is also the core of the structural diversity of the chemical components of Tripterygium wilfordii alkaloids.
[0004] Studies have shown that the roots of Tripterygium wilfordii are rich in 3-carboxy-α-methyl-2-pyridinebutyric acid and 3-carboxy-α-hydroxy-α-methyl-2-pyridinebutyric acid, which were named wilfordic acid and Hydroxywilfordic acid respectively by Professor BEROZA. The two types of structures, wilfordic acid and Hydroxy wilfordic acid, are typical iVA-NAs. The difference is that position 2 in the niacin structure is replaced by different isovaleric acid structures. However, in the past 70 years, there have been relatively few overall studies on wilfordic acid and hydroxy wilfordic acid, and there is no systematic chemical and pharmacological research.
[0005] Although the therapeutic effects of natural active ingredients from Tripterygium wilfordii plants in autoimmune diseases such as rheumatoid arthritis are clear, their clinical application is greatly limited by the potential toxic side effects, extremely narrow therapeutic window, poor solubility, and low bioavailability of the active ingredients. Therefore, the art urgently needs to provide a Tripterygium wilfordii plant extract with good efficacy and low toxicity for the treatment of autoimmune diseases such as rheumatoid arthritis. Summary of the invention
[0006] In view of this, the purpose of the present invention is to provide a low-toxic, high-efficiency, and effective Tripterygium wilfordii extract that can be used to treat autoimmune diseases such as rheumatoid arthritis and has significant therapeutic effects, as well as a preparation method and application thereof.
[0007] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:
[0008] The invention provides a method for preparing a low-toxic tripterygium wilfordii extract, comprising the following steps: reducing pressure and concentrating an ethyl acetate extract of a plant of the genus tripterygium to obtain an extract; redissolving the extract and then treating it with a chemical method, an enzyme method or a bionic method, taking a filtrate and adjusting the pH to below 3.5, purifying it with a polyamide column chromatography, collecting and concentrating the eluate to obtain the low-toxic tripterygium wilfordii extract; the chemical method is to add calcium hydroxide and keep the pH to above 11; the enzyme method is to add esterase; and the bionic method is to add mouse intestinal contents.
[0009] Preferably, the amount of calcium hydroxide added is 0.18-3.6 g per gram of extract according to the weight of the extract.
[0010] Preferably, the amount of the esterase added is 1000-100000 U per gram of extract according to the weight of the extract.
[0011] Preferably, the mouse intestinal contents include SD rat intestinal contents, C57 mouse intestinal contents or Kunming mouse intestinal contents.
[0012] Preferably, the amount of mouse intestinal contents added is 0.5-20 ml per gram of extract according to the weight of the extract.
[0013] Preferably, when polyamide column chromatography is used for purification, the sample loading flow rate is 0.1-10 column volumes / hour, 0.5-10 column volumes of purified water are used for elution, the elution flow rate is 0.1-10 column volumes / hour, and the purified water eluate is collected at the beginning of sample loading.
[0014] The present invention also provides a tripterygium wilfordii extract prepared by the above preparation method.
[0015] Preferably, the Tripterygium wilfordii extract includes one or more of nicotinic acid, isonicotinic acid, 2-(3-carboxybutyl)nicotinic acid, 4-(3-carboxybutyl)nicotinic acid, 2-(3-carboxy-3-hydroxybutyl)nicotinic acid, 4-(3-carboxy-3-hydroxybutyl)nicotinic acid, 2-(3-carboxy-2-butyl)nicotinic acid, 4-(3-carboxy-2-butyl)nicotinic acid, 2-(3-carboxy-3-hydroxy-2-butyl)nicotinic acid and 4-(3-carboxy-3-hydroxy-2-butyl)nicotinic acid.
[0016] The present invention also provides an application of the above preparation method or the above Tripterygium wilfordii extract in the preparation of a product for preventing and treating rheumatoid arthritis.
[0017] The present invention also provides a medicine for preventing and treating rheumatoid arthritis, wherein the active ingredient of the medicine comprises the above-mentioned Tripterygium wilfordii extract.
[0018] Beneficial effects of the present invention:
[0019] The present invention proposes for the first time a method for preparing a low-toxic and highly effective tripterygium wilfordii extract. The method is simple, and the active ingredients of the tripterygium wilfordii extract prepared by the preparation method of the present invention are clear, the effective parts are definite, the anti-rheumatoid arthritis effect is non-obvious toxicity and the drug efficacy is significant, the effect of treating autoimmune diseases such as rheumatoid arthritis is significantly better than that of existing tripterygium wilfordii preparations, and compared with existing tripterygium wilfordii preparations, there is no obvious toxicity. BRIEF DESCRIPTION OF THE DRAWINGS
[0020] Figure 1 This is the characteristic spectrum of the Tripterygium wilfordii extract of Example 1;
[0021] Figure 2 The chemical structure diagram of the indicative components of Tripterygium wilfordii extract;
[0022] Figure 3 The high resolution mass spectrometry extracted ion current spectrum of the Tripterygium wilfordii extract in Example 2;
[0023] Figure 4 The high-resolution mass spectrometry extracted ion current spectrum of the Tripterygium wilfordii extract of Example 3;
[0024] Figure 5 The results of different groups relieving joint and foot swelling in SD rat CIA model, where A is the joint index score result and B is the joint swelling degree result;
[0025] Figure 6 X-ray photos of the different groups showing the alleviating effects on joint deformation in the CIA model of SD rats;
[0026] Figure 7 This is the pharmacokinetic AUC curve of 2-(3-carboxybutyl) nicotinic acid component. DETAILED DESCRIPTION
[0027] The invention provides a method for preparing a low-toxic and high-efficiency tripterygium wilfordii extract, comprising the following steps: reducing pressure and concentrating an ethyl acetate extract of a plant of the genus tripterygium to obtain an extract; redissolving the extract and then treating it with a chemical method, an enzyme method or a bionic method, taking a filtrate and adjusting the pH to below 3.5, purifying it with a polyamide column chromatography, collecting and concentrating the eluate to obtain the low-toxic and high-efficiency tripterygium wilfordii extract; the chemical method is to add calcium hydroxide and keep the pH to above 11; the enzyme method is to add esterase; and the bionic method is to add mouse intestinal contents.
[0028] In the present invention, "Tripterygium wilfordii extract" refers to the compound of Tripterygium wilfordii alkaloid components in the extract, which is the main chemical component in the composition structure of the extract and plays the main therapeutic effect. Although the extract may also contain other components derived from the same plant, these other components are usually not chemical components that can effectively play a therapeutic effect in the extract. This is because their content is lower than the threshold value for playing a therapeutic effect or they themselves do not have the expected therapeutic effect. "Effective part" refers to an extract with relatively clear components composed of one or several categories of components extracted from a single plant, which can also be called an effective component or an effective intermediate ("Technical Guidelines for Quality Research of New Chinese Medicines (Trial), January 2021").
[0029] In the present invention, the Tripterygium wilfordii plant preferably includes Tripterygium wilfordii, Northeast Tripterygium wilfordii and Malus kunmingensis. The present invention has no particular limitation on the specific source of the Tripterygium wilfordii plant. In the present invention, the Tripterygium wilfordii plant ethyl acetate extract is preferably a Tripterygium wilfordii plant ethyl acetate extract obtained by ethyl acetate percolation, or a Tripterygium wilfordii plant ethyl acetate extract obtained by ethyl acetate reflux extraction, or a Tripterygium wilfordii plant ethyl acetate extract obtained by ethyl acetate ultrasonic extraction. In the present invention, when the Tripterygium wilfordii plant ethyl acetate extract is prepared by ethyl acetate percolation, the Tripterygium wilfordii plant is preferably crushed and then percolated with ethyl acetate. The amount of ethyl acetate used is preferably 5-15 times the weight of the Tripterygium wilfordii plant, more preferably 10 times. The material part of the Tripterygium wilfordii plant raw material is preferably the root, root bark, root core stem or / and leaf of the plant. The conditions for the reduced pressure concentration are preferably reduced pressure concentration at 58° C. to a density of 1.1-1.7. The solvent used to redissolve the extract preferably includes water, methanol, ethanol, propanol, butanol, dichloromethane, chloroform, ether or tetrahydrofuran. The amount of the redissolving solvent used is preferably 10-100 ml per gram of extract, more preferably 50 ml.
[0030] In the present invention, the chemical reaction is preferably carried out by adding calcium hydroxide. The amount of calcium hydroxide added is preferably 0.18-3.6 g per gram of extract according to the weight of the extract, and more preferably 0.72 g. The reaction temperature is preferably 25-100°C, and more preferably 80°C. The reaction time is preferably 0.5-12 hours, and more preferably 4 hours. The reaction is preferably a stirring reaction.
[0031] In the present invention, the enzymatic reaction is preferably an esterase reaction, and the amount of the esterase added is preferably 1000-100000U per gram of extract according to the weight of the extract, and more preferably 10000U. The esterase is preferably derived from pig liver, and the temperature of the esterase reaction is preferably 35-39°C, more preferably 37°C, and the reaction time is preferably 0.5-12h, more preferably 4h.
[0032] In the present invention, the bionic method is preferably to add mouse intestinal contents, and the mouse intestinal contents are obtained by dissecting rats after anesthesia and taking the contents of the colon. The mouse intestinal contents preferably include SD rat intestinal contents, C57 mouse intestinal contents or Kunming mouse intestinal contents, and the amount of the mouse intestinal contents added is preferably 0.5-20ml per gram of extract according to the weight of the extract, and more preferably 10ml. In the present invention, after adding the mouse intestinal contents, it is preferred to add a sterile culture medium, and the sterile culture medium is EE broth culture medium, and the amount of the sterile culture medium added is preferably 10-200ml per gram of extract according to the weight of the extract, and more preferably 100ml. The temperature of the bionic method reaction is preferably 25-39°C, and more preferably 37°C, and the reaction time is preferably 0.5-48h, and more preferably 12h.
[0033] After the reaction is completed, the solvent for adjusting the pH of the filtrate is preferably a 5% sulfuric acid solution. In the present invention, the polyamide column is preferably a 80-100 mesh polyamide column, and the amount of the polyamide is preferably one-fifth of the sample volume. When performing polyamide column chromatography purification, the sample flow rate is preferably 0.1-10 times the column volume / hour, more preferably 0.5 times the column volume / hour, 0.5-10 times the column volume of purified water elution, more preferably 2 times the column volume of purified water elution, and the elution flow rate is preferably 0.1-10 times the column volume / hour, more preferably 0.5 column volume / hour. In the present invention, the purified water eluate is collected at the beginning of the sample loading, and the condition for concentrating the eluate is preferably 65°C reduced pressure concentration.
[0034] The present invention also provides a tripterygium wilfordii extract prepared by the above preparation method. In the present invention, the tripterygium wilfordii alkaloid extract preferably includes one or more of nicotinic acid, isonicotinic acid, 2-(3-carboxybutyl)nicotinic acid, 4-(3-carboxybutyl)nicotinic acid, 2-(3-carboxy-3-hydroxybutyl)nicotinic acid, 4-(3-carboxy-3-hydroxybutyl)nicotinic acid, 2-(3-carboxy-2-butyl)nicotinic acid, 4-(3-carboxy-2-butyl)nicotinic acid, 2-(3-carboxy-3-hydroxy-2-butyl)nicotinic acid and 4-(3-carboxy-3-hydroxy-2-butyl)nicotinic acid, and more preferably includes all of the above.
[0035] The present invention also provides a use of the above preparation method or the above Tripterygium wilfordii extract in preparing a product for preventing and treating rheumatoid arthritis. In the present invention, the type of the product preferably includes medicine.
[0036] The present invention also provides a medicine for preventing and treating rheumatoid arthritis, wherein the active ingredient of the medicine comprises the above-mentioned Tripterygium wilfordii extract.
[0037] In the medicine of the present invention, the above-mentioned Tripterygium wilfordii extract is preferably used as the only active ingredient. The medicine preferably also includes pharmaceutical excipients, and the pharmaceutical excipients preferably include: fillers, diluents, carriers, excipients, disintegrants, adhesives, lubricants, flavoring agents, surfactants, colorants, coating agents, propellants or stabilizers. In the present invention, the dosage form of the medicine preferably includes tablets, sugar-coated tablets, film-coated tablets, enteric-coated tablets, capsules, oral liquids, lozenges, granules, electuary, pills, powders, pastes, pills, suspensions, powders, solutions, injections, suppositories, ointments, plasters, creams, sprays, aerosols, drops or patches.
[0038] The technical solutions provided by the present invention are described in detail below in conjunction with the embodiments, but they should not be construed as limiting the protection scope of the present invention.
[0039] In the following embodiments, unless otherwise specified, all of them are conventional methods.
[0040] Unless otherwise specified, the materials and reagents used in the following examples can be obtained from commercial sources.
[0041] Example 1
[0042] The raw medicinal materials were purchased from Dechang, Yunnan, and were identified as Tripterygium hypoglaucum (Levl.) Hutch by researcher Qu Xianyou of Chongqing Institute of Traditional Chinese Medicine. The root of Kunming Crabapple with root bark removed is taken, crushed and passed through a No. 10 standard pharmacopoeia sieve, and filtrated with 10 times the amount of ethyl acetate. After filtrating is complete, the root is concentrated under reduced pressure at 58°C to a density of 1.1 to obtain an extract of ethyl acetate of Tripterygium wilfordii; the extract is re-dissolved in anhydrous ethanol, the amount of anhydrous ethanol is 50 ml / g of the extract, 0.72 g / 100 ml of calcium hydroxide solution is added and stirred evenly, and the pH is kept above 11, the amount of calcium hydroxide solution is 100 ml / g of the extract, stirred at 80°C for 4 hours, filtered, the filtrate is added with 5% sulfuric acid solution to adjust the pH to 3, and purified by polyamide column chromatography, the polyamide particle size is 80-100 mesh, the amount of polyamide is one-fifth of the sample volume, the sample flow rate is 0.5 times the column volume / hour, eluted with 2 times the column volume of purified water, the elution flow rate is 0.5 times the column volume / hour, the purified water eluate is collected at the beginning of sample loading and concentrated under reduced pressure at 65°C; the concentrate is the refined and purified Tripterygium wilfordii extract.
[0043] The obtained Tripterygium wilfordii extract was subjected to HPLC injection analysis (conditions): using a UV detector and AQ-C18 chromatographic column (4.6 mm × 150 mm, 5 μm) of a Shimadzu HPLC system. The mobile phase was acetonitrile (A) and 0.1% formic acid solution (B), gradient elution (0–40 min, 5%-5% A; 40–43 min, 5%–90% A; 43–55 min, 90%–90% A; 55–58 min, 90%–5% A; 58–80 min, 5%–5% A), flow rate 1.0 mL / min, column temperature 30 °C, injection volume 10 μL, UV detection wavelength 262 nm, the results are as follows Figure 1 shown.
[0044] Preparative chromatography separation and purification: Preparative chromatography uses BUCHI Pure medium pressure flash chromatography purification system, and the chromatographic conditions are: AQ-C18 chromatographic column (20mm×250mm, 10μm). The mobile phase is methanol (A) and 0.2% formic acid solution (B) (ratio: 5-95), isocratic elution, flow rate 10.0mL / min, column temperature 30℃, UV detection wavelength 262nm. The isolated compounds include nicotinic acid, isonicotinic acid, 2-(3-carboxybutyl)nicotinic acid, 4-(3-carboxybutyl)nicotinic acid, 2-(3-carboxy-3-hydroxybutyl)nicotinic acid, 4-(3-carboxy-3-hydroxybutyl)nicotinic acid, 2-(3-carboxybutan-2-yl)nicotinic acid, 4-(3-carboxybutan-2-yl)nicotinic acid, and 4-(3-carboxybutan-2-yl)nicotinic acid. acid), 2-(3-carboxy-3-hydroxy-2-butyl) nicotinic acid (2-(3-carboxy-3-hydroxybutan-2-yl) nicotinic acid) and 4-(3-carboxy-3-hydroxybutan-2-yl) nicotinic acid (4-(3-carboxy-3-hydroxybutan-2-yl) nicotinic acid) components, the results are shown in Figure 2 .
[0045] Example 2
[0046] The root bark of the Malus kunmingensis (same as in Example 1) was removed, crushed and passed through a No. 10 standard pharmacopoeia sieve, and filtrated with 10 times the amount of ethyl acetate. After filtrating was complete, the root was concentrated under reduced pressure at 58° C. to a density of 1.7. After concentrated under reduced pressure, an ethyl acetate extract of Tripterygium wilfordii was obtained; the extract was re-dissolved in anhydrous ethanol, the amount of anhydrous ethanol was 50 ml / g of the extract, and esterase (Sigma, 46058-50MG-F) was added for incubation, and the amount of esterase added was 10000 U / g of the extract. The mixture was reacted at 37° C. for 4 hours, filtered, and the filtrate was adjusted to pH 3 by adding 5% sulfuric acid solution. The mixture was purified by polyamide column chromatography. The polyamide particle size was 80-100 mesh. The amount of polyamide was one-fifth of the sample volume. The sample flow rate was 0.5 column volume / hour. The sample was eluted with 2 column volumes of purified water. The elution flow rate was 0.5 column volume / hour. The purified water eluate was collected at the beginning of sample loading and concentrated under reduced pressure at 65° C. The concentrate was the refined and purified Tripterygium wilfordii extract.
[0047] The sample of Tripterygium wilfordii extract was diluted with methanol, centrifuged at 12000rpm for 10min, filtered through a 0.22μm filter membrane, and analyzed by Q-TOF / MS (AB SCIEX 4600 high-resolution mass spectrometry system). The ESI-Production-IDA acquisition mode was used for data acquisition and high-resolution mass spectrometry extracted ion current spectrum was obtained. The results are shown in Figure 3 shown.
[0048] Example 3
[0049] Take the root bark of Malus kunmingensis (same as Example 1), crush it and pass it through a No. 10 standard pharmacopoeia sieve, percolate it with 10 times the amount of ethyl acetate, and after percolation is complete, concentrate it under reduced pressure at 58°C to a density of 1.5, and concentrate it under reduced pressure to obtain an ethyl acetate extract of Tripterygium wilfordii; re-dissolve the extract in anhydrous ethanol, use anhydrous ethanol in an amount of 50 ml / g of extract, and incubate it with the intestinal contents of SD rats (the SD rats were dissected after anesthesia, and the contents of the colon were taken). The rat intestinal contents were added in an amount of 10 ml / g extract, and a sterile culture medium (EE broth) was added in an amount of 100 ml / g extract, reacted at 37°C for 4 hours, filtered, and the filtrate was adjusted to pH 3 by adding 5% sulfuric acid solution, and purified by polyamide column chromatography. The polyamide particle size was 80-100 mesh, the amount of polyamide was one-fifth of the sample volume, the sample flow rate was 0.5 column volume / hour, and 2 column volumes of purified water were used for elution. The elution flow rate was 0.5 column volume / hour. The purified water eluate was collected from the start of sample loading and concentrated under reduced pressure at 65°C; the concentrate was the refined and purified Tripterygium wilfordii extract.
[0050] The sample of Tripterygium wilfordii extract was diluted with methanol, centrifuged at 12000rpm for 10min, filtered through a 0.22μm filter membrane, and analyzed by Q-TOF / MS (AB SCIEX 4600 high-resolution mass spectrometry system). The ESI-Production-IDA acquisition mode was used for data acquisition and high-resolution mass spectrometry extracted ion current spectrum was obtained. The results are shown in Figure 4 shown.
[0051] Example 4
[0052] Example 1 Effect of the Tripterygium wilfordii extract on relieving foot swelling in SD rats with CIA model
[0053] CIA-induced SD rat rheumatoid arthritis model: Take 20.9 mg of collagen (chicken) and dissolve it in 5.225 mL of 0.1 mol / L glacial acetic acid solution, place it in a 4°C refrigerator overnight, and get a 4 mg / mL collagen (chicken) solution. Then take 78.5 mg of inactivated BCG dry powder, place it in a sterile mortar, add 4.107 mL of complete Freund's adjuvant to fully grind and mix, place it in a cell ultrasonic, set the frequency to 10%, ultrasonic time 2s, pause 5s, repeat the ultrasonic operation until BCG becomes small particles and is basically uniform, place it in a 75°C water bath for 2h, and make 20 mg / mL Freund's complete adjuvant. Take 4mg / mL CCII collagen bath solution (3.3mL) and an equal volume of 20mg / mL FCA (3.3mL) and mix and emulsify in an ultrasonic cell crusher at 10% frequency to make a mixed emulsifier of 2mg / mL collagen + 10mg / mL FCA. Keep the collagen cold during the emulsification process (prepare ice packs or crushed ice in advance). Primary immunization: Injection: Inject 0.1mL / rat mixed emulsifier into the right hind toe of the rat. Reinforced immunization: Injection: Inject 0.1mL / rat mixed emulsifier into the right hind toe of the rat. The foot volume of CIA-induced SD rheumatoid arthritis rats was measured regularly using a swelling meter.
[0054] The mice without modeling were used as the normal control group, and the rats with successful modeling were randomly divided into three groups, namely the model group (CIV group), the methotrexate group (CIV+methotrexate group) and the Tripterygium wilfordii extract group (CIV+iVA-NA group), where the iVA-NA dosage was 3.75g crude drug / kg, intragastric administration, once a day, for 42 consecutive days. Methotrexate dosage: Phase I: 2.4mg / kg body weight, intraperitoneal injection, 3 times a week, for 12 consecutive days, 3 rats died; Phase II: 7 days of drug withdrawal; Phase III: 1.2mg / kg body weight, intraperitoneal injection, 1 administration with an interval of 2 days, for 23 consecutive days, and a treatment cycle of 42 days. The normal control group and the model control group were given the corresponding volume of 0.5% CMC-Na solution, and the administration volume was 1mL / 100g body weight.
[0055] The joint index score and joint swelling degree of each group were calculated before and after the administration.
[0056] Joint index score: Before administration (day 0) and on days 7, 14, 21, and 42 of administration, the rats were scored according to the degree of swelling and redness of the ankle joints and toe joints of the forelimbs and hindlimbs and the affected joint index. 0 points: normal; 1 point: 1 joint is red and swollen; 2 points: 2 or more joints are red and swollen; 3 points: severe swelling and redness of the sole below the ankle joint; 4 points: all paws including the ankle joint are red and swollen and cannot bear weight. The four limbs were scored separately, and the cumulative sum was the joint index.
[0057] Joint swelling: The rat foot volume was measured using a swelling meter and the rat foot volume value was recorded. The joint swelling was expressed as the percentage of joint swelling, which was (the rat foot volume after administration-the rat foot volume before modeling) / the rat foot volume before modeling × 100%. The model was successfully established when the joint swelling percentage was greater than 10%.
[0058] The results are as follows Figure 5 shown.
[0059] After the administration, the animals in each group were X-rayed. The results are shown in Figure 6 After administration, the joint deformity of the rats in the model group was significantly improved. The results show that the Tripterygium wilfordii extract prepared by the present invention has a significant therapeutic effect on rheumatoid arthritis.
[0060] Example 5
[0061] Pharmacokinetic Analysis of 2-(3-Carboxybutyl) Nicotinic Acid
[0062] SD rats, all male, were divided into 3 groups, 3 rats in each group, namely high-dose group, medium-dose group, and low-dose group. The prepared test solution was diluted to 12 (high-dose group, high concentration group), 6 (medium-dose group, medium concentration group), and 3 (low-dose group, low concentration group) mg·Kg -1 A single intragastric administration was performed. A blank blood sample was collected before administration. Blood was collected from the forearm cephalic vein at 0.5, 1, 1.5, 2, 3, 6, 8, and 24 hours after intragastric administration. About 1.5 ml of whole blood was placed in a sodium heparin anticoagulant tube and incubated at 3000 r·min. -1Centrifuge for 10 minutes, separate the plasma, and then divide it into two tubes (take 50 μL from one tube, and place the remaining plasma in the other tube for standby use), and freeze it at -80°C for standby use. Accurately pipette 50 μL of mixed blank plasma into a 1.5 mL EP tube, accurately add 20 μL of water, vortex mix for 30 seconds, then add 400 μL of methanol-acetonitrile (1:1, v / v) solution, vortex mix for 2 minutes, centrifuge at 12000 rpm for 15 minutes, and take 400 μL of the supernatant into an EP tube. The processed samples were subjected to quantitative analysis of the target components of the plasma samples using an LC-MS-MS instrument, and the pharmacokinetic parameters of the plasma sample content determination results were detected using the DAS3.0 pharmacokinetic software. The results are shown in Tables 1 and Figure 7 As shown, the results showed that within the corresponding dosage range, the dosage of 2-(3-carboxybutyl) nicotinic acid was significantly positively correlated with the AUC parameter.
[0063] Table 1 Pharmacokinetic parameters
[0064]
[0065]
[0066] Note: L01, L02, L03 are low-dose groups, M01, M02, M03 are medium-dose groups, H01, H02, H03 are high-dose groups.
[0067] Example 6
[0068] Acute toxicity test of Tripterygium wilfordii extract
[0069] The sample preparation was prepared according to the method shown in Example 1, and the extract was obtained according to the single-dose toxicity test. 6-week-old KM mice, all male, 18-22g. The experimental animal provider is Beijing Weitong Lihua Experimental Animal Technology Co., Ltd. (Production License No.: SCXK (Beijing) 2016-0006), Experimental Animal Certificate No.: No. 110011210100421925, and the quality inspection unit is Beijing Weitong Lihua Experimental Animal Technology Co., Ltd. The experimental animals were raised in an SPF environment (No. 34, Nanshan Road, Huangjuya, Nan'an District, Chongqing, SYXK (Yu) 2022-0005), temperature: 20.5-24.5°C, humidity: 41-69%, and the experimental facility inspection was conducted by the Chongqing Experimental Animal Quality Inspection Center, which met the general environmental requirements of GB 14925-2010 standard. After the animals were purchased, the Animal Management Department inspected and accepted the animals according to the ordering standards. The animals that passed the inspection were uniquely marked on the left ear with ear tags and entered quarantine and adaptive feeding at the same time. The animals were quarantined and adaptively fed for 7 days. The experimental animals were fed with SPF rat and mouse maintenance feed (batch number 21043213, Beijing Keao Xieli Feed Co., Ltd.), which was adequately supplied daily and allowed rats to ingest freely. The feed production license number was SCXK (Beijing) 2019-0003. The feed ingredient test report was provided by the manufacturer and met the requirements of GB 14924.3-2010, GB / T 18823-2010, GB / T14924.2-2001, and GB / T14924.1-2001. The drinking water for feeding was purified water, bottled, and the water bottle was changed daily. The rats ingested freely. The water quality test was tested by the Nan'an District Center for Disease Control and Prevention in Chongqing and met the requirements of GB 5749-2006. A single-dose toxicity test was used to conduct acute toxicity tests on different extracted parts of Tripterygium wilfordii. The dose that caused all death of the test animals in the preliminary experiment was taken as the highest dose. Different dose ranges were set, and 14 days was the longest observation period. The toxicity of the test substance can be evaluated through acute oral toxicity tests and LD50 determination.
[0070] The results showed that the Tripterygium wilfordii extract obtained in Example 1 did not show toxic effects at a dosage of 500g crude drug Kg. By consulting the literature for comparison, the clinically recommended dosage of the root of Torch Flower is 1.5-3g (Root of Torch Flower-Sichuan Traditional Chinese Medicine Standard (2010 Edition)), and the clinically recommended dosage of the Tripterygium wilfordii medicinal material is 6-12g (Tripterygium wilfordii-Shandong Traditional Chinese Medicine Standard (Publicized in 2022)). The results of previous studies showed that the LD50 of Torch Flower Root for intragastric administration was 136.38g crude drug / kg, and its 95% confidence limit was 123.06-152.51g crude drug / kg. The Tripterygium wilfordii extract of the present invention did not show obvious toxicity when the dosage was much larger than the clinically recommended dosage.
[0071] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.
Claims
1. A method for preparing a Tripterygium wilfordii extract, characterized in that: The method comprises the following steps: reducing pressure and concentrating the ethyl acetate extract of a plant of the genus Tripterygium to obtain an extract; re-dissolving the extract and then subjecting it to a chemical treatment, taking a filtrate and adjusting the pH to below 3.5, purifying it by polyamide column chromatography, collecting and concentrating the eluate to obtain a Tripterygium wilfordii extract; the chemical method comprises adding calcium hydroxide and maintaining the pH to above 11; The amount of calcium hydroxide added is 0.18-3.6 g per gram of extract according to the weight of the extract; When polyamide column chromatography is used for purification, the sample loading flow rate is 0.1-10 column volumes / hour, 0.5-10 column volumes of purified water are used for elution, the elution flow rate is 0.1-10 column volumes / hour, and the purified water eluate is collected at the beginning of sample loading; The plant of the genus Tripterygium is Tripterygium wilfordii, Tripterygium wilfordii in northeast China or Malus kunmingensis.
2. The Tripterygium wilfordii extract prepared by the preparation method according to claim 1.
3. The Tripterygium wilfordii extract according to claim 2, characterized in that The tripterygium wilfordii extract includes one or more of nicotinic acid, isonicotinic acid, 2-(3-carboxybutyl)nicotinic acid, 4-(3-carboxybutyl)nicotinic acid, 2-(3-carboxy-3-hydroxybutyl)nicotinic acid, 4-(3-carboxy-3-hydroxybutyl)nicotinic acid, 2-(3-carboxy-2-butyl)nicotinic acid, 4-(3-carboxy-2-butyl)nicotinic acid, 2-(3-carboxy-3-hydroxy-2-butyl)nicotinic acid and 4-(3-carboxy-3-hydroxy-2-butyl)nicotinic acid.
4. Use of the preparation method according to claim 1 or the Tripterygium wilfordii extract according to any one of claims 2 to 3 in the preparation of products for preventing and treating rheumatoid arthritis.
5. A drug for preventing and treating rheumatoid arthritis, characterized in that: The active ingredient of the medicine is the Tripterygium wilfordii extract according to claim 2 or 3.
